Merck KGaA and F-star in €1bn dealGerman Merck KGaA has secured an option on UKs F-Star Biotechnology Ltds preclinical bispecific PD-L1/LAG checkpoint inhibitor FS118 and four candidates in discovery stage. more ➔
Bicycle raises £40mCambridge-based cancer company Bicycle Therapeutics has raised £40m to advance its clinical pipeline of peptide-based conjugates with antibody-like binding properties. more ➔
EC and EMA provide Brexit guidanceUK-based drug developers and contract manufacturers are set to find partners in the European Economic Area (EEA) to uphold Orphan Drug Designation, MAA or transfer their current UK based site of batch … more ➔
Addex further improves liquidityFollowing a private placement worth CHF3m in February, Swiss allosteric modulator specialist Addex Therapeutics has increased its capital to finance clinical studies of dipraglurant in Parkinsons and … more ➔
AMO Pharma receives FDA Fast Track Status London-based orphan drug developer AMO Pharmas drug AMO-02 has been granted FDA fast track status as treatment for congenital myotonic dystrophy, a sub-indication muscular dystrophy. more ➔
Biocorp partners with VirbacFrench drug delivery specialist Biocorp S.A. (Issoire) has signed an industrialisation contract with Virbac, one of the top-ten vet-med makers. more ➔
Janssen speeds up guselkumab approval proc...Janssen speeds up US approval of psoriasis antibody guselkumab and targets further indications. more ➔
Abzenas partner True North Therapeutics...British Abzena plc has announced that True North Therapeutics (TNT) will be taken over by Bioverativ Inc. Bioverativ will further develop TNT’s complement factor C1-blocking antibody TNT009, developed … more ➔
RA: Sanofi/Regeneron IL-6R blocker FDA-app...Following the EMAs recommendation for EU approval of sarilumab as second-line treatment for rheumatoid arthritis, French drug giant Sanofi and partner Regeneron have also been given the green light … more ➔
Safety event delays US market approval of...Top-Line Phase 3 data of Amgens/UCBs osteoporosis antibody romosozumab in postmenopausal women suggest efficacy but uncover a new safety signal. more ➔
